Novartis (NVS) – Reuters
-
Novartis to cut 680 jobs in product development
-
Exclusive-Novartis in the lead to acquire cancer drug developer MorphoSys-sources
-
Novartis lifts 2023 earnings forecast for third time
-
Novartis shareholders vote in favour of Sandoz spin-off
-
Novartis raises 2023 forecast, maps out Sandoz spin-off
-
Bausch + Lomb buys Novartis drugs for $1.75 billion to boost eye-care portfolio
-
Novartis buys Chinook for $3.5 billion in race to treat rare kidney disease
-
Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
-
Amgen sues Novartis to block generic osteoporosis, bone cancer drugs
-
Novartis to pay $30 million to health plans, consumers over Exforge antitrust claims
-
Novartis to cut its Irish workforce by up to 25%
-
Novartis plans to close a Sandoz plant in North Carolina
-
Novartis to cut up to 8,000 jobs globally
-
Novartis to cut thousands of jobs in global revamp - paper
-
Novartis sees steady growth as weighs selling generics arm
-
Blackstone, Carlyle consider joint bid for Novartis generics unit - Bloomberg News
-
Novartis CEO says Sandoz attracting interest - paper
-
Novartis chairman says all options open for Sandoz unit - report
-
Novartis may divest generic unit Sandoz as price pressures mount
-
Novartis to close Swiss plant, 50 jobs to go
-
Novartis CEO says COVID-19 makes valuing takeover targets tougher
-
Novartis halts distribution of its Zantac versions amid probe into impurities
-
Novartis names Bulto as new head of U.S. drugs business
-
Novartis raises full-year targets, aims to settle U.S. lawsuit
-
Novartis appoints Susanne Schaffert to lead oncology business
-
Novartis to cut 2,550 jobs in Switzerland, UK in profit push
-
Trump thanks Novartis, Pfizer for not raising drug prices
-
Swiss prosecutors will not pursue Novartis over Trump lawyer payments
-
Novartis CEO Narasimhan remakes drugmaker's leadership as Wyss exits
-
Novartis generics arm says may sell or end some products
-
Roche, Novartis' Italian heads risk trial for alleged market rigging: sources
-
Novartis to shut U.S. generics plant, cut 450 jobs
-
FDA panel backs Novartis' pioneering new cancer gene therapy
-
Novartis has assets to sell, investors wary of what it might buy
-
Novartis to cut around 500 jobs in Switzerland, add 350
-
Exclusive: Novartis in talks to sell some central nervous system drugs - sources
-
Novartis willing to sell Roche stake without demanding premium - CEO
-
Novartis executive exodus complicates drugmaker's rebuilding job
-
Anacor skin cream succeeds in studies, fuels takeover expectations
Back to NVS Stock Lookup
